SEMINAR ON NONCOMPARTMENTAL PHARMACOKINETICS

Similar documents
PHARMACOKINETICS. Dr. M.Mothilal Assistant professor

Pharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal

BASIC PHARMACOKINETICS AND PHARMACODYNAMICS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS

Injectable modified release products

Biomath M263 Clinical Pharmacology

Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs. Nikunjkumar Patel, Simcyp Limited

Study (s) Degree Center Acad. Period Grado de Farmacia FACULTY OF PHARMACY 3 Annual PDG Farmacia-Nutrición Humana y Dietética

Pharmacokinetic & Pharmacodynamic Data Analysis

Biopharmaceutics. Lecture :1. Module Introduction and Introduction to Biopharmaceutics

Conventional versus Physiologically-Based (PB)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with PB-IVIVC

BIOPHARMACEUTICS AND PHARMACOKINETICS

BIOPHARMACEUTICS AND PHARMACOKINETICS. University of Alcalá. Academic year 2016/17 3 rd Year 1 st Season

II Semester M.PHARM (PHARMACEUTICS) MPH2A.1: ADVANCED PHYSICAL PHARMACEUTICS 3 Hrs/Week THEORY

Oral Delivery of Drugs

Official Letter from the DOH

On applications of conservation laws in pharmacokinetics

Bioavailability and Bioequivalence Studies

Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists

KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D

Dr. M.Mothilal Assistant professor

In silico Prediction of Bioavailability of Pharmaceutical Formulations Using Population Pharmacokinetic Model Simulation

Making PK Analysis Easier: The New ADaM Data Standard ADNCA

Course Curriculum for Master Degree in Pharmaceutical Technology

Pharmacokinetics in clinical oncology

IVIVC IMPORTANCE OF IVIVC AND METHODS OF ESTABLISHING IVIVC

Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics

BIOEQUIVALENCE: BLOOD LEVEL BIOEQUIVALENCE STUDY

Institute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1

Application of PBPK Models in Assessment of Bioequivalence

Eurofins ADME BIOANALYSES Your partner in drug development

Mechanistic IVIVC Using the Simcyp ADAM Model. Make SCIENCE out of IVIVC

How do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug?

In Vitro-In Vivo Correlation:

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997

In vitro - In vivo Correlation: From Theory to Applications

Guideline on quality of oral modified release products

Guideline on quality of oral modified release products

Fig. 4. A two-compartment pharmacokinetic model.

Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2

Comparison of the pharmacokinetics of chloroquine after single

VICH GL52 on Bioequivalence: blood level bioequivalence study

Assessment of BE. Assessment of bioequivalence of implants: Appropriate study design, metrics, and acceptance criteria

NORTH CAROLINA STATE UNIVERSITY Raleigh, North Carolina

Application of Direct Search Optimization for Pharmacokinetic Parameter Estimation

Session 7 Clinical Trial Assessment Bioequivalence Studies

Unit V APPLICATIONS OF PHARMACOKINETICS

PREDICTIVE PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE FLOATING TABLETS

Role of PBPK based virtual trials modeling in generic product development and regulation

European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

ORAL BIOAVAILABILITY ASSESSMENT

Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation

Nature Biotechnology: doi: /nbt.1691

MEDICINES CONTROL COUNCIL

INTRODUCTION TO PHARMACOLOGY

Σχεδιασμός κλινικών μελετών βιοϊσοδυναμίας (DESIGN OF BIOEQUIVALENCE STUDIES) To demonstrate that two (or more) medicinal products are bioequivalent

Line extension of immediate release products

Clinically Relevant Specifications (CRS): A Regulatory Perspective

Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action

Course Title PHARMACEUTICAL FORMULATION, DEVELOPMENT & BIOPHARMACEUTICS. Lecture : 05. Practical : 04. Course Credit. Tutorial : 00.

KEY WORDS Pharmacokinetics, modeler, hands-on, safety, practical class, clinical training.

Pharmacokinetic investigation of the absorption of oxprenolol

Science and Quality Assurance, Part 2: PK/QA

Development of biopharmacy

Basic Principles for Conducting Phase I Trials in the Japanese Population Prior to Global Clinical Trials

Toxicokinetic models and their applications

Revised guideline on the conduct of bioequivalence studies for veterinary medicinal products

In vitro in vivo correlations (IVIVC) can be summarized

Compartmental Pharmacokinetic Analysis. Dr Julie Simpson

INTRODUCTION TO CLINICAL PHARMACY

From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase

Simultaneous in vivo Quantification and Metabolite Identification of Plasma Samples Using High Resolution QTof and Routine MS E Data Analysis

Guidance for Industry

PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis

Optimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances

VELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS

QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS

Pharmacokinetics as applied to in vitro and animal models

High affinity target binding: a cause of non-linear Pharmacokinetics of drugs (Target mediated drug disposition: TMDD)

PHAR 7633 Chapter 23 Pharmacodynamic Models and Physiologically Based Pharmacokinetic Models

Pharmacokinetic / pharmacodynamic modeling and simulation in the design and analysis of Randomized Concentration-Controlled Trials (RCCTs)

Pharmacokinetic and pharmacodynamic evaluation of a new vascular calcification inhibitor (INS-3001) in rats

Modern Pharmaceutics. Second Edition, Revised and Expanded. edited by GILBERT S. BANKER University of Minnesota Minneapolis, Minnesota

PHARMACOKINETICS OF DROPERIDOL IN SURGICAL PATIENTS UNDER DIFFERENT CONDITIONS OF ANAESTHESIA

Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator

Translational Pharmaceutics : a unique platform to accelerate early oncology development

Clinical Pharmacokinetics The Mcq Approach Telford Press

ICH Reflection Paper Further Opportunities for Harmonization of Standards for Generic Drugs 1

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) GUIDELINE ON THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS

Clinical Pharmacology

Approval Review of Generic Drugs. Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D.

PHARMACOKINETICS OF COLISTIN IN CHICKENS AT DIFFERENT AGES

Public Assessment Report Scientific discussion. Etoricoxib Orion (etoricoxib) SE/H/1554/01-04/DC

CRED: Understanding Clinical Development Programme June 2018 Day one Chairperson: Steve Pinder, Envestia Ltd

Maximizing the Value and Utility of ADaM for Pharmacokinetic Analyses and Reporting: Much More than just ADPC and ADPP

Biowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA

The research work highlights the development and evaluation of. bioavailability of drugs. The buccal route can bypass the first-pass

The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability. WHO Biowaiver Guideline in Regulatory Practice

In vivo predictive biopharmaceutics tools for oral drug delivery

Transcription:

SEMINAR ON NONCOMPARTMENTAL PHARMACOKINETICS Presented by: Ch. Karthik Siva Chaitanya M.Pharm (1 st sem),pharmaceutics UCPSc,KU. 1

Contents: Introduction to noncompartmental pharmacokinetic approach Differences between compartment and noncompartment models Concepts of noncompartmental model Statistical moments theory-mean residence time Different pharmacokinetic parameters in noncompartment model Sem,UCPSc,KU 2

Noncompartment pharmacokinetics is a new approach devised to study the time course of drug in the body with out assuming any compartment model. Based on the statistical moment theory. Model independent method Overcomes some of the drawbacks associated with classical compartment modeling. Basic assumption is that drug or metabolite follows first-order kinetics. Sem,UCPSc,KU 3

Noncompartment and Compartment models Comparison Compartment models Noncompartment models These require elaborate assumptions to fit the data Curve fitting of experimental data using computers. It is a tedious method. Applicable to linear and nonlinear pharmacokinetics Do not require assumptions to compartment model. Simple algebraic equations. No curve fitting and no computers Applicable to linear pharmacokinetics. C1 - time profile is regarded as expressions of exponents These are useful for most of the situations, though assumptions of modeling are involved. C1 time profile is regarded as statistical distribution. Particularly useful for the applications of clinical pharmacokinetics, bioavailability, and bioequivalence studies. Sem,UCPSc,KU 4

Advantages: Derivation of PK parameters is easy, because of simple algebraic equations Mathematical treatment remains same, for drug or metabolite, provided elimination follows first order kinetics Drug disposition kinetics need not be described in detail Sem,UCPSc,KU 5

Disadvantages: Information regarding plasma drug concentrationtime profile is expressed as an average Generally not useful for describing the time course of drug in the blood It is applicable only for linear pharmacokinetics Sem,UCPSc,KU 6

Statistical Moment Theory Statistical moment: A mathematical description of a discrete distribution of data. Statistical moments calculated from a set of concentration-time data represent an estimate of the true moment (or the true probability density function (PDF)that describes the true relationship between concentration and time). Statistical moment theory provides a unique way to study time-related changes in macroscopic events. Assume the drug molecules are eliminated according to a kinetic function, f(t) = C 0 e kt Sem,UCPSc,KU 7

Eq.1 2 [AUC] 0 = C dt 1 3 [AUMC] 0 = t x C. dt Sem,UCPSc,KU 8

I.V. bolus injection Calculation of AUC and AUMC Sem,UCPSc,KU 9

Mean residence time(mrt): The term mean residence time (MRT) describes the average time for all the drug molecules to reside in the body. Sem,UCPSc,KU 10

MRT represents the time for 63.2% of drug eliminated when given i.v. bolus injection. It is analogous to plasma elimination half life, t1/2, i.e., 50% elimination. Like half life, MRT is a function of both distribution and elimination For i.v bolus dose Sem,UCPSc,KU 11

In noncompartmental terms, k is constant equal to ratio of clearance to Vss Vss is volume of distribution at steady state Plasma elimination half life : t 1/2 = t1/2 = 0.693MRT MRTiv is used for comparison. For eg: following constant rate of infusion 0.693 k 10 Where T = duration of infusion Sem,UCPSc,KU 12

DRUG ABSORPTION: MAT(Mean absorption time) is defined as the differences in mean residence time (MRT) after different modesof administration. MAT = MRTni MRTiv MRTni = mean residence time of drug by noninstantaneous route, h MRTiv = mean residence time of drug by i.v. bolus injection Same equation is used for i.m. injection Sem,UCPSc,KU 13

When absorption follows zero order T = time over which absorption takes place, h MAT can be used for comparision of dosage forms Sem,UCPSc,KU 14

OTHER APPLICATIONS OF MRT Mean Dissolution Time(MDT) MDT=MRTtest-MRTsoln In oral administration, MRToral=MRTiv+1/Ka For evaluation of absorption data, MAT=MRTtest-MRTiv MAT=1/Ka Ka is first order absorption rate constant Sem,UCPSc,KU 15

Drug Clearance: After iv bolus administration, At steady state after constant rate iv infusion Ko is rate of infusion ; Css is steady state concentration By using extraction ratio Cl=Q(ER) Sem,UCPSc,KU 16

APPARENTVOLUME OF DISTRIBUTION: is volume of distribution at steady state independent of elimination Vss Vss =i.v dose(aumc)/(auc) If drug is given by constant rate i.v infusion Where Ko is infusion rate; is duration of infusion Sem,UCPSc,KU 17

Steady State Plasma Drug Concentration: The Css is a function of the effective rateof dosing and total body clearance of thedrug in a patient Sem,UCPSc,KU 18

AUCss is AUC from t=0 to t= during a dosinginterval at steady state F is fraction bioavailable Method of superposition is used for predicting steady state concentration on repetitive dosing from data obtained after a single dose. Sem,UCPSc,KU 19

Predicting the Time to Steady State: Time required for the drug to reach steady state, i.e., 99%, takes 6.65 half lives. In extravascular route (or prolongedrelease drug products), the time requiredto attain ss takes longer than predicted bybiological half life In multicompartment disposition, timerequired to attain to ss is shorter than that predicted by terminal half life Sem,UCPSc,KU 20

In noncompartmentmodels, when the drug isadministered repetitive dosing, fss AUC = area under the curve in single dose Sem,UCPSc,KU 21

Bioavailability: Bioavailability refers to the fractional dose of a dosage form reaches systemic circulation. For i.v. bolus injection, bioavailability is referred as unity (=1) Bioavailability (F) of a dosage form Sem,UCPSc,KU 22

Fraction metabolised: Fraction metabolized, Fm = AUC x 1 AUC 1 AUC x 1 is area under the curve of metabolite concentrationin plasma versus time from zero to infinity AUC 1 is the total area under the metabolite concentration time curve after a equimolar intravenous dose of a metabolite Sem,UCPSc,KU 23

CONCLUSION: The noncompartmental pharmacokinetic methods permit a comprehensive pharmacokinetic analysis with out resort to curve fitting,sophisticated computers or tedious mathematical equations. Although these methods cannot be applied to all pharmacokinetic problems,they are useful for most problems and are particularly useful for the clinical application of pharmacokinetics. Sem,UCPSc,KU 24

References: Milo Gibaldi, Biopharmaceutics and clinical pharmacokinetics, 4 th edition,pg no 17-26 D.Perrier,M.Gibaldi Pharmacokinetics, 2 nd edition, pg no 409-417 Leon Shargel,Applied biopharmaceutics and pharmacokinetics,5 th edition,pg no 717-753 V.Venkateshwarlu,Biopharmaceutics and pharmacokinetics, pg no 309-330 www.pharainfo.net Sem,UCPSc,KU 25

THANK YOU Sem,UCPSc,KU 26